4/6 patients had viral reduction greater than 1 log. To me the data doesn't seem that exciting considering all these patients responded well to interferon alpha. Hopefully we see better data at higher dosage. Thanks for posting the abstract. Whats your thought on this data?
Dewo - thanks for the abstract. On it's face it doesn't look particularly good (only one patient with greater than 1 log reduction at day 29). But looking closer is a lot(!) more encouraging:
Clearly 2 weeks between dosing is not adequate. Given the PK it was always known that QoW was unlikely to be particularly effective. (I remember a cc where an analyst asked why bother and the answer was a verbal shrug of the shoulders - a Eh, why not.)
I believe that the piece of data more indicative of eventual clinical efficacy is the data at 1 week after the second dosing where the average log reduction is 1.75. While I don't remember the details of viral kinetics I believe that at this point patients should be on the steady ramp down portion of the viral load curve (i.e. well after the transient spike down). So with any luck patients getting 1.5 every week will be well into very viable treatment range. And patients in the 4th cohort (3.0 once per week) could well show stellar efficacy.
Here's to hoping they can get the 3rd cohort wrapped up in time to see it in the meeting - and maybe even the fourth (although if I remember correctly they were in the 3rd cohort in the last cc where they mentioned cohort status (Q cc in early Aug))
ZGEN – Why is the ifn-lambda program in the slow lane? It looks like the drug is on target to reach the market around the time when interferon therapies will be starting to become less relevant.
Market Data 
Markets 
AI
